+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xeljanz"

Tofacitinib Global Market Report 2024 - Product Thumbnail Image

Tofacitinib Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Janus Kinase (JAK) Inhibitors Global Market Report 2024 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Ankylosing Spondylitis Global Market Report 2024 - Product Thumbnail Image

Ankylosing Spondylitis Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Psoriatic Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 180 Pages
  • Global
From
From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
XELJANZ Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

XELJANZ Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 150 Pages
  • Global
From
Ankylosing Spondylitis - Pipeline Insight, 2021 - Product Thumbnail Image

Ankylosing Spondylitis - Pipeline Insight, 2021

  • Clinical Trials
  • May 2021
  • 80 Pages
  • Global
From
Anti-rheumatic drug - Forecasts from 2020 to 2025 - Product Thumbnail Image

Anti-rheumatic drug - Forecasts from 2020 to 2025

  • Report
  • April 2020
  • 120 Pages
  • Global
From
Market Spotlight: Axial Spondyloarthritis (axSpA) - Product Thumbnail Image

Market Spotlight: Axial Spondyloarthritis (axSpA)

  • Report
  • March 2021
  • 52 Pages
  • Global
From
Loading Indicator

Xeljanz (tofacitinib) is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking certain proteins that are involved in the body's inflammatory response. Xeljanz is taken orally, usually twice daily, and is available in both tablet and suspension form. It is typically used in combination with other medications, such as methotrexate or biologic drugs. Xeljanz is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It has become a popular treatment option for immune disorders, due to its effectiveness and convenience. Companies in the Xeljanz market include Pfizer, which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are numerous companies that provide support services, such as patient assistance programs and educational materials. Show Less Read more